Zoetis Inc. Class A Common Stoc (ZTS) 28.60 $ZTS
Favourable Rulings, Topline Results, Earnings Schedules, Approvals, and New Advisory Boards - Analyst Notes on Lilly, UnitedHealth Group, Valeant, Forest Laboratories, and Zoetis
PR Newswire - Fri Apr 11, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Eli Lilly & Co. (NYSE: LLY), UnitedHealth Group, Inc. (NYSE: UNH), Valeant Pharmaceuticals International, Inc. (NYSE: VRX), Forest Laboratories Inc. (NYSE: FRX), and Zoetis Inc. (NYSE: ZTS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Pharma Stocks on our Radar -- Research on AVANIR Pharma, Zoetis, Salix Pharma, and Jazz Pharma
PR Newswire - Thu Apr 10, 11:31AM CDT
The trading session on Wednesday, April 09, 2014 ended on a positive note as the Dow Jones Industrial Average finished at 16,437.18, up 1.11% and the NASDAQ Composite closed at 4,183.90, up 1.72%. The S&P 500 finished the session 1.09% higher at 1,872.18. The gains were broad based as eight out of ten sectors posted gains. The S&P 500 Health Care Sector Index finished the day 2.11% higher at 673.27, and the same has gained 2.86% in the previous three months. Investor-Edge has initiated coverage on the following equities: Investor-Edge has initiated coverage on the following equities: AVANIR Pharmaceuticals Inc. (NASDAQ: AVNR), Zoetis Inc. (NYSE: ZTS), Salix Pharmaceuticals Ltd (NASDAQ: SLXP) and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ). Free technical research on AVNR, ZTS, SLXP and JAZZ can be downloaded upon signing up at:
Veterinary Vaccines - Global Strategic Overview 2014
M2 - Tue Apr 08, 9:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6cbpkt/veterinary) has announced the addition of the "Veterinary Vaccines - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Veterinary Vaccines in US$ Million by the following Product Segments: Companion Animal Vaccines (Canine Vaccines, & Feline Vaccines), and Livestock Vaccines (Porcine Vaccines, Bovine Vaccines, Poultry Vaccines, Ovine Vaccines, Equine Vaccines, & Other Animal Vaccines). The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 100 companies including many key and niche players such as: - Bayer HealthCare AG (Germany) - Biogenesis-Bago (Argentina) - Boehringer Ingelheim GmbH (Germany) - Ceva Sant? Animale (France) - Heska Corporation (US) - Indian Immunologicals Ltd (India) - Lohmann Animal Health (US) - Merck Animal Health (US) - Merial Ltd. (US) - Protein Sciences Corporation (US) - Virbac SA (France) - Zoetis Inc. (US) Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview & Outlook 2. Market Trends & Issues 3. Product Overview 4. Notes On Select Animal Diseases 5. Product Launches And Innovations 6. Recent Industry Activity 7. Focus On Select Global Players 8. Global Market Perspective III. Market 1. The United States 2. Europe 3. Asia-Pacific 4. Latin America 5. Rest Of World IV. Competitive Landscape Total Companies Profiled: 100 (including Divisions/Subsidiaries 123) - The United States (24) - Canada (2) - Japan (6) - Europe (36) - France (4) - Germany (
- The United Kingdom (5) - Italy (3) - Spain (4) - Rest of Europe (12) - Asia-Pacific (Excluding Japan) (28) - Latin America (19) - Africa (5) - Middle East (3) For more information visit http://www.researchandmarkets.com/research/6cbpkt/veterinary
3 ETFs to Watch on Solid GrubHub Debut - ETF News And Commentary
Sweta Killa - ZACKS - Mon Apr 07, 1:00PM CDT
GrubHub's successful market debut put these ETFs in focus.
Trial Results, Product Approvals, Upcoming Meetings, Dividend Announcements, and Product Comparisons - Analyst Notes on Amgen, Abbott, Express Scripts, Zoetis, and Edwards
PR Newswire - Wed Apr 02, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Amgen Inc. (NASDAQ: AMGN), Abbott Laboratories (NYSE: ABT), Express Scripts Holding Company (NASDAQ: ESRX), Zoetis Inc. (NYSE: ZTS), and Edwards Lifesciences Corp. (NYSE: EW). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Zoetis to Host Webcast and Conference Call on First Quarter 2014 Financial Results
Business Wire - Mon Mar 31, 7:31AM CDT
Zoetis Inc.(NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (EDT) on Tuesday, May 6, 2014. Chief Executive Officer Juan Ramon Alaix and Executive Vice President and Chief Financial Officer Rick Passov will review first quarter 2014 financial results and respond to questions from financial analysts during the call.
Zoetis updates and corrects its Q2 2014 dividend details
M2 - Thu Mar 27, 6:05AM CDT
The board of directors of Zoetis (NYSE:ZTS), an animal health company, declared on Wednesday its dividend of USD0.072 per share of its common stock for the second quarter.
CORRECTING and REPLACING Zoetis Declares Second Quarter 2014 Dividend
Business Wire - Wed Mar 26, 7:03PM CDT
First paragraph, second sentence of release should read: The dividend is to be paid on June 2, 2014 to holders of record on April 28, 2014 (instead of: The dividend is to be paid on June 2, 2014 to holders of record on April 27, 2014).
Zoetis Declares Second Quarter 2014 Dividend
Business Wire - Wed Mar 26, 3:30PM CDT
The Board of Directors of Zoetis Inc.(NYSE:ZTS) declared a second quarter dividend payable to holders of the company's common stock of $0.072 per share. The dividend is to be paid on June 2, 2014 to holders of record on April 27, 2014.
First Week Of May 17th Options Trading For Zoetis (ZTS)
at The Street - Wed Mar 26, 11:19AM CDT
Investors in Zoetis Inc saw new options become available this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ZTS options chain for the new May 17th contracts and identified one put and...
Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 1:17AM CDT
Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews
Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 1:17AM CDT
Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
3 Stocks Near 52-Week Lows Worth Buying
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 25, 3:25PM CDT
Just as we examine companies each week that may be rising past their fair values , we can also find companies trading at what may be bargain prices. While many investors would rather have nothing to do with companies wallowing at 52-week lows, I...
New Product Offerings, Development and Research Collaboration, Upcoming Investor Conference, and Board Election - Analyst Notes on CVS Caremark, Teva, Zoetis, McKesson, and Mylan
PR Newswire - Mon Mar 24, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding CVS Caremark Corporation (NYSE: CVS), Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), Zoetis, Inc. (NYSE: ZTS), McKesson Corporation (NYSE: MCK), and Mylan, Inc. (NASDAQ: MYL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Pharmaceutical Equities under Review -- Research on Zoetis, Mylan, AVANIR Pharma and Actavis
PR Newswire - Fri Mar 21, 10:11AM CDT
The trading session on Thursday, March 20, 2014 ended on a positive note as the Dow Jones Industrial Average finished at 16,331.05, up 0.67% and the NASDAQ Composite closed at 4,319.29, up 0.27%. The S&P 500 finished the session 0.60% higher at 1,872.01. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 686.29, down 0.02%, whereas, the index has advanced 0.77% in the last one month. Investor-Edge has initiated coverage on the following equities: Zoetis Inc. (NYSE: ZTS), Mylan Inc. (NASDAQ: MYL), AVANIR Pharmaceuticals Inc. (NASDAQ: AVNR) and Actavis PLC (NYSE: ACT). Free technical research on ZTS, MYL, AVNR and ACT can be downloaded upon signing up at:
3 Growth Stocks Worth Considering for Your Roth IRA
Nicole Seghetti, The Motley Fool - Motley Fool - Wed Mar 19, 8:17AM CDT
With less than one month left before the tax-filing deadline, it's time to fund a Roth IRA if you haven't done so already. Let's briefly discuss why a Roth IRA is so essential in saving for your retirement. Then we'll look at three great growth...
Equine Healthcare Market Report, 2013 - 2019: Diagnostic Products, Therapeutic Products and Supplement Products
M2 - Fri Mar 14, 9:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qdnqld/equine_healthcare) has announced the addition of the "Equine Healthcare Market Report, 2013 - 2019: Diagnostic Products, Therapeutic Products and Supplement Products" report to their offering. The global equestrian market is a multi-billion dollar industry that comprises horse racing and betting, leisure and competitive riding and has spawned and supports multifarious secondary markets. The equine healthcare market ranks as one of the key secondary markets. This report exclusively studies the market for equine healthcare from varied aspects such as, equine diagnostic products, equine therapeutic products and equine supplement products. It is thus classified into three prime segments namely equine diagnostic products market, equine therapeutic products market and equine supplement products market. The market size and forecast for the period 2013-2019, in terms of USD million, considering 2012 as the base year has been provided for each segment and sub-segments in the report. The compound annual growth rate (CAGR) for each segment and sub-segments has been provided for the forecast period from 2013-2019. Scope of the Report Equine Diagnostic Products Market, by Type - Equine Pregnancy and Gestation Diagnostic Products Market -- Equine UltraSound Devices Market -- Equine Urine Test Kits Market - Equine Genotyping Analysis Products Market -- Breed Quality Analyzers/Genotype Analyzers Kits Market -- Genetic Disease Identification Products/Semen Quality Analyzers Market Equine Therapeutic Products Market, by Type - Equine Vaccines Market - Equine Antibacterials Market - Equine Antivirals Market - Equine Antiprotozoals Market - Equine Dopamine Agonists Market - Equine Anti-inflammatory Drugs Market - Equine Laxatives Market Equine Supplement Products Market, by Type - Equine Performance Supplements Market -- Equine Proteins and Amino Acids Supplements Market -- Equine Vitamin Supplements Market -- Equine Electrolyte Supplements Market -- Other Equine Performance Supplements Market - Equine Protection Products Market -- Equine Protection Products Market -- Equine Prosthetics Market Companies Mentioned - Affymetrix, Inc. - Bayer - Boerhringer Ingelheim Vetmedica, Inc. (BIVI) - Elanco Animal Health - Equine Diagnostics - Equine Orthotics and Prosthetics - Equine Products (UK) Ltd. - Merck Animal Health - Purina Mills, LLC - Signostics Limited - Zoetis, Inc. For more information visit http://www.researchandmarkets.com/research/qd...healthcare
Zoetis to Participate in Jefferies Animal Health Summit
Business Wire - Thu Mar 13, 8:20AM CDT
Zoetis Inc. (NYSE:ZTS) will participate in the Jefferies Animal Health Summit on Thursday, March 27, at the Jefferies Conference Center in New York, NY. Juan Ramon Alaix, chief executive officer of Zoetis, will represent the company and respond to questions from analysts. He is scheduled to present at 9:30 a.m. ET.
Appointments, Regulatory Approvals, Conference Participation Schedule, Acquisitions, and Increased Stake - Analyst Notes on Perrigo, Zoetis, ISIS, GSK, and AstraZeneca
PR Newswire - Thu Mar 13, 7:31AM CDT
Today, Analysts Review released its analysts' notes regarding Perrigo Company (NYSE: PRGO), Zoetis Inc. (NYSE: ZTS), ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS), GlaxoSmithKline plc (NYSE: GSK), and AstraZeneca plc (NYSE: AZN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Favourable Rulings, Topline Results, Earnings Schedules, Approvals, and New Advisory Boards - Analyst Notes on Lilly, UnitedHealth Group, Valeant, Forest Laboratories, and Zoetis
PR Newswire - Fri Apr 11, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Eli Lilly & Co. (NYSE: LLY), UnitedHealth Group, Inc. (NYSE: UNH), Valeant Pharmaceuticals International, Inc. (NYSE: VRX), Forest Laboratories Inc. (NYSE: FRX), and Zoetis Inc. (NYSE: ZTS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Pharma Stocks on our Radar -- Research on AVANIR Pharma, Zoetis, Salix Pharma, and Jazz Pharma
PR Newswire - Thu Apr 10, 11:31AM CDT
The trading session on Wednesday, April 09, 2014 ended on a positive note as the Dow Jones Industrial Average finished at 16,437.18, up 1.11% and the NASDAQ Composite closed at 4,183.90, up 1.72%. The S&P 500 finished the session 1.09% higher at 1,872.18. The gains were broad based as eight out of ten sectors posted gains. The S&P 500 Health Care Sector Index finished the day 2.11% higher at 673.27, and the same has gained 2.86% in the previous three months. Investor-Edge has initiated coverage on the following equities: Investor-Edge has initiated coverage on the following equities: AVANIR Pharmaceuticals Inc. (NASDAQ: AVNR), Zoetis Inc. (NYSE: ZTS), Salix Pharmaceuticals Ltd (NASDAQ: SLXP) and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ). Free technical research on AVNR, ZTS, SLXP and JAZZ can be downloaded upon signing up at:
Veterinary Vaccines - Global Strategic Overview 2014
M2 - Tue Apr 08, 9:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6cbpkt/veterinary) has announced the addition of the "Veterinary Vaccines - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Veterinary Vaccines in US$ Million by the following Product Segments: Companion Animal Vaccines (Canine Vaccines, & Feline Vaccines), and Livestock Vaccines (Porcine Vaccines, Bovine Vaccines, Poultry Vaccines, Ovine Vaccines, Equine Vaccines, & Other Animal Vaccines). The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 100 companies including many key and niche players such as: - Bayer HealthCare AG (Germany) - Biogenesis-Bago (Argentina) - Boehringer Ingelheim GmbH (Germany) - Ceva Sant? Animale (France) - Heska Corporation (US) - Indian Immunologicals Ltd (India) - Lohmann Animal Health (US) - Merck Animal Health (US) - Merial Ltd. (US) - Protein Sciences Corporation (US) - Virbac SA (France) - Zoetis Inc. (US) Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview & Outlook 2. Market Trends & Issues 3. Product Overview 4. Notes On Select Animal Diseases 5. Product Launches And Innovations 6. Recent Industry Activity 7. Focus On Select Global Players 8. Global Market Perspective III. Market 1. The United States 2. Europe 3. Asia-Pacific 4. Latin America 5. Rest Of World IV. Competitive Landscape Total Companies Profiled: 100 (including Divisions/Subsidiaries 123) - The United States (24) - Canada (2) - Japan (6) - Europe (36) - France (4) - Germany (
- The United Kingdom (5) - Italy (3) - Spain (4) - Rest of Europe (12) - Asia-Pacific (Excluding Japan) (28) - Latin America (19) - Africa (5) - Middle East (3) For more information visit http://www.researchandmarkets.com/research/6cbpkt/veterinary 3 ETFs to Watch on Solid GrubHub Debut - ETF News And Commentary
Sweta Killa - ZACKS - Mon Apr 07, 1:00PM CDT
GrubHub's successful market debut put these ETFs in focus.
Trial Results, Product Approvals, Upcoming Meetings, Dividend Announcements, and Product Comparisons - Analyst Notes on Amgen, Abbott, Express Scripts, Zoetis, and Edwards
PR Newswire - Wed Apr 02, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Amgen Inc. (NASDAQ: AMGN), Abbott Laboratories (NYSE: ABT), Express Scripts Holding Company (NASDAQ: ESRX), Zoetis Inc. (NYSE: ZTS), and Edwards Lifesciences Corp. (NYSE: EW). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Zoetis to Host Webcast and Conference Call on First Quarter 2014 Financial Results
Business Wire - Mon Mar 31, 7:31AM CDT
Zoetis Inc.(NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (EDT) on Tuesday, May 6, 2014. Chief Executive Officer Juan Ramon Alaix and Executive Vice President and Chief Financial Officer Rick Passov will review first quarter 2014 financial results and respond to questions from financial analysts during the call.
Zoetis updates and corrects its Q2 2014 dividend details
M2 - Thu Mar 27, 6:05AM CDT
The board of directors of Zoetis (NYSE:ZTS), an animal health company, declared on Wednesday its dividend of USD0.072 per share of its common stock for the second quarter.
CORRECTING and REPLACING Zoetis Declares Second Quarter 2014 Dividend
Business Wire - Wed Mar 26, 7:03PM CDT
First paragraph, second sentence of release should read: The dividend is to be paid on June 2, 2014 to holders of record on April 28, 2014 (instead of: The dividend is to be paid on June 2, 2014 to holders of record on April 27, 2014).
Zoetis Declares Second Quarter 2014 Dividend
Business Wire - Wed Mar 26, 3:30PM CDT
The Board of Directors of Zoetis Inc.(NYSE:ZTS) declared a second quarter dividend payable to holders of the company's common stock of $0.072 per share. The dividend is to be paid on June 2, 2014 to holders of record on April 27, 2014.
First Week Of May 17th Options Trading For Zoetis (ZTS)
at The Street - Wed Mar 26, 11:19AM CDT
Investors in Zoetis Inc saw new options become available this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ZTS options chain for the new May 17th contracts and identified one put and...
Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 1:17AM CDT
Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews
Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 1:17AM CDT
Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
3 Stocks Near 52-Week Lows Worth Buying
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 25, 3:25PM CDT
Just as we examine companies each week that may be rising past their fair values , we can also find companies trading at what may be bargain prices. While many investors would rather have nothing to do with companies wallowing at 52-week lows, I...
New Product Offerings, Development and Research Collaboration, Upcoming Investor Conference, and Board Election - Analyst Notes on CVS Caremark, Teva, Zoetis, McKesson, and Mylan
PR Newswire - Mon Mar 24, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding CVS Caremark Corporation (NYSE: CVS), Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), Zoetis, Inc. (NYSE: ZTS), McKesson Corporation (NYSE: MCK), and Mylan, Inc. (NASDAQ: MYL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Pharmaceutical Equities under Review -- Research on Zoetis, Mylan, AVANIR Pharma and Actavis
PR Newswire - Fri Mar 21, 10:11AM CDT
The trading session on Thursday, March 20, 2014 ended on a positive note as the Dow Jones Industrial Average finished at 16,331.05, up 0.67% and the NASDAQ Composite closed at 4,319.29, up 0.27%. The S&P 500 finished the session 0.60% higher at 1,872.01. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 686.29, down 0.02%, whereas, the index has advanced 0.77% in the last one month. Investor-Edge has initiated coverage on the following equities: Zoetis Inc. (NYSE: ZTS), Mylan Inc. (NASDAQ: MYL), AVANIR Pharmaceuticals Inc. (NASDAQ: AVNR) and Actavis PLC (NYSE: ACT). Free technical research on ZTS, MYL, AVNR and ACT can be downloaded upon signing up at:
3 Growth Stocks Worth Considering for Your Roth IRA
Nicole Seghetti, The Motley Fool - Motley Fool - Wed Mar 19, 8:17AM CDT
With less than one month left before the tax-filing deadline, it's time to fund a Roth IRA if you haven't done so already. Let's briefly discuss why a Roth IRA is so essential in saving for your retirement. Then we'll look at three great growth...
Equine Healthcare Market Report, 2013 - 2019: Diagnostic Products, Therapeutic Products and Supplement Products
M2 - Fri Mar 14, 9:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qdnqld/equine_healthcare) has announced the addition of the "Equine Healthcare Market Report, 2013 - 2019: Diagnostic Products, Therapeutic Products and Supplement Products" report to their offering. The global equestrian market is a multi-billion dollar industry that comprises horse racing and betting, leisure and competitive riding and has spawned and supports multifarious secondary markets. The equine healthcare market ranks as one of the key secondary markets. This report exclusively studies the market for equine healthcare from varied aspects such as, equine diagnostic products, equine therapeutic products and equine supplement products. It is thus classified into three prime segments namely equine diagnostic products market, equine therapeutic products market and equine supplement products market. The market size and forecast for the period 2013-2019, in terms of USD million, considering 2012 as the base year has been provided for each segment and sub-segments in the report. The compound annual growth rate (CAGR) for each segment and sub-segments has been provided for the forecast period from 2013-2019. Scope of the Report Equine Diagnostic Products Market, by Type - Equine Pregnancy and Gestation Diagnostic Products Market -- Equine UltraSound Devices Market -- Equine Urine Test Kits Market - Equine Genotyping Analysis Products Market -- Breed Quality Analyzers/Genotype Analyzers Kits Market -- Genetic Disease Identification Products/Semen Quality Analyzers Market Equine Therapeutic Products Market, by Type - Equine Vaccines Market - Equine Antibacterials Market - Equine Antivirals Market - Equine Antiprotozoals Market - Equine Dopamine Agonists Market - Equine Anti-inflammatory Drugs Market - Equine Laxatives Market Equine Supplement Products Market, by Type - Equine Performance Supplements Market -- Equine Proteins and Amino Acids Supplements Market -- Equine Vitamin Supplements Market -- Equine Electrolyte Supplements Market -- Other Equine Performance Supplements Market - Equine Protection Products Market -- Equine Protection Products Market -- Equine Prosthetics Market Companies Mentioned - Affymetrix, Inc. - Bayer - Boerhringer Ingelheim Vetmedica, Inc. (BIVI) - Elanco Animal Health - Equine Diagnostics - Equine Orthotics and Prosthetics - Equine Products (UK) Ltd. - Merck Animal Health - Purina Mills, LLC - Signostics Limited - Zoetis, Inc. For more information visit http://www.researchandmarkets.com/research/qd...healthcare
Zoetis to Participate in Jefferies Animal Health Summit
Business Wire - Thu Mar 13, 8:20AM CDT
Zoetis Inc. (NYSE:ZTS) will participate in the Jefferies Animal Health Summit on Thursday, March 27, at the Jefferies Conference Center in New York, NY. Juan Ramon Alaix, chief executive officer of Zoetis, will represent the company and respond to questions from analysts. He is scheduled to present at 9:30 a.m. ET.
Appointments, Regulatory Approvals, Conference Participation Schedule, Acquisitions, and Increased Stake - Analyst Notes on Perrigo, Zoetis, ISIS, GSK, and AstraZeneca
PR Newswire - Thu Mar 13, 7:31AM CDT
Today, Analysts Review released its analysts' notes regarding Perrigo Company (NYSE: PRGO), Zoetis Inc. (NYSE: ZTS), ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS), GlaxoSmithKline plc (NYSE: GSK), and AstraZeneca plc (NYSE: AZN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
